XRpro Announces Assignment of Patents from Los Alamos National Security

CAMBRIDGE, Mass., Nov. 3, 2014 /PRNewswire/ -- XRpro Corp, a subsidiary of Caldera Pharmaceuticals, Inc. (providers of a unique platform for drug discovery and development services which feature high throughput ion channel assays for the pharmaceutical industry) today announced the assignment of an important series of patents from Los Alamos National Security, LLC.  Caldera's XRpro® and MXRF® technologies are protected by a solid IP estate, including more than 50 issued and pending patents, based on innovations made at Caldera Pharmaceuticals, Inc. and Los Alamos National Laboratory.

Tim Tyson, Acting CEO and Chairman of XRpro Corp. commented, "With this assignment we now control the entire portfolio of patents surrounding our XRpro® technology." He continued, "This patent assignment significantly extends both the subject matter and geographic reach of our intellectual property."

"The acquisition and assignment of these patents is a major advance for the company," said Benjamin Warner, Founder and Chief Scientific Officer of XRpro Corp. "We are pleased that we were able to complete this long and successful relationship with Los Alamos National Laboratory."

About Caldera Pharmaceuticals, Inc.

Caldera Pharmaceuticals, Inc. and its wholly owned subsidiary, XRpro Corp., provides a unique platform for drug discovery and development services featuring high throughput ion channel assays for the pharmaceutical industry. The company's proprietary advances in X-ray fluorescence provide measurements that would otherwise be difficult or impossible. XRpro® technology directly measures the activity of a drug target, without the need for costly and artefact-causing chemical dyes or radiolabels.

Investor Contact:

Aimee Boutcher or Daniel Boutcher

[email protected]

973 332-0120

This release includes forward-looking statements on the Company's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the expected contribution of Mr. Altman and our technology. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in the Company's forward-looking statements include, among others, our ability to sell and market our technology and services, the contribution and integration of the Company's new management and the other factors described in the Company's Report on Form 10-K for the year ended December 31, 2012 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

SOURCE Caldera Pharmaceuticals, Inc.